A Phase 3 interventional study of Exparel and 0.25% bupivacaine in Anesthesia, sponsored by Montefiore Medical Center. Terminated at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-03-20.
Sponsored by Montefiore Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Total knee and hip replacements are some of the most common orthopedic procedures that require aggressive postoperative pain management. This management helps us to improve clinical outcomes such as participation in early physical therapy, hospital discharge, and patient satisfaction. Based on the recent anatomical evidence and the investigator's knowledge of the complexity of the knee joint innervation the investigator proposes a new regional anesthesia technique that provides a complete sensory blockade and better analgesia while preserving the quadriceps strength and avoiding the potential for foot drop caused by inadvertent blockade of the common peroneal nerve.
This is an assessor-blinded randomized controlled trial evaluating the efficacy of liposomal bupivacaine (Exparel) in patients undergoing Total Knee Arthroplasty. The primary outcome of this study is the proportion of patients "fit to discharge" on postoperative day one. Recently, liposomal bupivacaine (LB) (Exparel) was introduced into clinical practice, using a lipid-based depot (DepoFoam) technology for sustained release of bupivacaine. LB (Exparel) uses this technology to extend the delivery of bupivacaine, a local anesthetic that has been used in clinical practice for decades for peripheral nerve block, spinal, and epidural analgesia and anesthesia. This formulation prolongs the duration of analgesia of bupivacaine for up to 72 hours with a single injection. The study was designed to compare two of our current standard therapies:
Montefiore Medical Center is the lead sponsor of 416 studies on the registry; 69 are open to participants now.
Of its 88 completed or terminated interventional studies of FDA-regulated products, 76 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.25% bupivacaine in patients undergoing total knee arthroplasty
Drug: 0.25% bupivacaine
0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
Drug: Exparel · Drug: 0.25% bupivacaine
1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
0.25% bupivacaine in patients undergoing total knee arthroplasty
Also known as: liposomal
AM-PAC Score to Measure Patients Fitness for Discharge
AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge.
Time frame: Post-Operation Day 1
Opioid Consumption During the First 48 Hours After TKA Surgery
Monitor how much opioid patient consumes
Time frame: During the first 48 hours after surgery
Pain Scores During 48 Hrs Postoperatively
Will use Numeric Pain Rating Scale (NPRS) to measure pain with 0 being no pain and 10 being the worst pain.
Time frame: 48 hours postoperatively
| Milestone | Bupivicaine | Bupivicaine + Exparel |
|---|---|---|
| Started | 13 | 12 |
| Completed | 13 | 12 |
| Not completed | 0 | 0 |
AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge.
| score on scale | Bupivicaine | Bupivicaine + Exparel |
|---|---|---|
| AM-PAC Score to Measure Patients Fitness for Discharge | 23 (19 to 23) | 23 (21 to 24) |
Monitor how much opioid patient consumes
| milligram | Bupivicaine | Bupivicaine + Exparel |
|---|---|---|
| Opioid Consumption During the First 48 Hours After TKA Surgery | 90 (39 to 118) | 76 (25 to 128) |
Will use Numeric Pain Rating Scale (NPRS) to measure pain with 0 being no pain and 10 being the worst pain.
| score on scale | Bupivicaine | Bupivicaine + Exparel |
|---|---|---|
| Pain Scores During 48 Hrs Postoperatively | 4 (2.5 to 7) | 4 (3 to 5) |
Collected over Adverse event data were collected up until 48 hours post operation.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bupivicaine | 0/13 (0%) | 0/13 (0%) | 0/13 (0%) |
| Bupivicaine + Exparel | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) |
| Age, Categorical(Participants) | Bupivicaine | Bupivicaine + Exparel | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 6 | 6 |
| >=65 years | 13 | 6 | 19 |
| Age, Continuous(years) | Bupivicaine | Bupivicaine + Exparel | Total |
|---|---|---|---|
| Median | 71 (66 to 75) | 67 (58 to 77) | 70 (63 to 75) |
| Sex: Female, Male(Participants) | Bupivicaine | Bupivicaine + Exparel | Total |
|---|---|---|---|
| Female | 10 | 8 | 18 |
| Male | 3 | 4 | 7 |
| Race and Ethnicity Not Collected(Participants) | Bupivicaine | Bupivicaine + Exparel | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Bupivicaine | Bupivicaine + Exparel | Total |
|---|---|---|---|
| United States | 13 | 12 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — All study data will be collected and entered into the computer database. Each subject will be assigned to a random number code and the key linking the code and the subject identifier will be stored in a locked cabinet. The computer database will be password protected and will be kept on the Montefiore drive. The research manager is responsible for auditing the consistency of the data transcribed from the paper case report form to the computer. A protocol violation log will be maintained and all protocol violations will be reported to the Institutional Review Board and Data Safety Monitoring Board. The planned interim analysis (half way through the recruitment) will be mainly focused on the adverse events, rather than the efficacy of the procedure.
Ran from Oct 2017 to primary completion in Jun 2018, 8 months.
Results were first posted in Mar 2020, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.